Pharmacogenetics: From discovery to patient care

American Journal of Health-System Pharmacy

Volumn 66, Issue 7, 2009, Pages 625-637

  Shin, Jaekyu ^a   Kayser, Steven R ^a   Langaee, Taimour Y ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Food and drug administration (U.S.); Labeling; methodology; Patient care; Pharmacists; Pharmacogenetics; Research

Indexed keywords

ABACAVIR; ATOMOXETINE; AZATHIOPRINE; BIOLOGICAL MARKER; BUSULFAN; CAPECITABINE; CARBAMAZEPINE; CELECOXIB; CETUXIMAB; DASATINIB; ERLOTINIB; FLUOROURACIL; FLUOXETINE; IMATINIB; IRINOTECAN; ISONIAZID; MARAVIROC; MERCAPTOPURINE; PRIMAQUINE; RASBURICASE; RETINOIC ACID; RIFAMPICIN; TAMOXIFEN; TRASTUZUMAB; VALPROIC ACID; WARFARIN;

CLINICAL PRACTICE; DRUG LABELING; DRUG RESEARCH; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; PATIENT CARE; PHARMACIST; PHARMACOGENETICS; PHARMACY; PRIORITY JOURNAL; REVIEW;

EID: 63449090236     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080170     Document Type: Review

References (116)

1. Beutler E. Drug-induced hemolytic anemia. Pharmacol Rev. 1969; 21:73-103.
2. Vogel F. [Modern problems of human genetics.] Ergeh Inn Med Kinderheilkd. 1959; 12:52-125. In German.
3. Hopkins MM, Ibarreta D, Gaisser S et al. Putting pharmacogenetics into practice. Nat Bwtechnol. 2006; 24:403-10.
4. Gelehrter TD, Collins FS, Ginsburg DG. Principles of medical genetics. 2nd ed. Baltimore: Williams & Wilkins; 1998:341-50.
5. Strachan TS, Read AP. Human molecular genetics. 3rd ed. New York: Garland; 2004.
6. Redon R, Ishikawa S, Fitch KR et al. Global variation in copy number in the human genome. Nature. 2006; 444:444- 54.
7. Oak Ridge National Laboratory. Human Genome Project information. www.ornl.gov/sci/techresources/ Human-Genome/home.shtml (accessed 2009 Jan 12).
8. International HapMap Project. International HapMap Project homepage. www.hapmap.org (accessed 2009 Jan 12).
9. Frueh FW, Amur S, Mummaneni P et al. Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy. 2008; 28:992-8.
10. Food and Drug Administration. Innovation or stagnation: challenge and opportunity of the critical path to new medical product,www.fda.gov/oc/ initiatives/cnticalpath/whitepaper.html (accessed 2008 Mar 30).
11. Food and Drug Administration. Guidance for industry: pharmacogenomics data submission, www.fda.gov/cder/ guidance/6400fnl.pdf (accessed 2008 Mar 30).
12. Rogers JF, Kidd RS. Assessing home health care pharmacists' knowledge of cytochrome P450 pharmacogenetics. J Pharm Technol. 2002; 18:248-53.
13. Sansgiry SS, Kulkarni AS. The human genome project: assessing confidence in knowledge and training requirements for community pharmacists. Am J Pharm Educ. 2003; 67:article 39.
14. Streetman DS. Emergence and evolution of pharmacogenetics and pharmaco- genomics in clinical pharmacy over the past 40 years. Ann Pharmacother. 2007; 41:20.
15. Accreditation Council for Pharmacy Education. Accreditation standards and guidelines for the professional program in pharmacy leading to the doctor of pharmacy degree,www.acpe-accredit.org/deans/standards.asp (accessed 2008 Mar 30).
16. Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chesh. 2004;126(3, suppl):429S- 456S.
17. Veenstra DL, Blough DK, Higashi MK et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther. 2005; 77:353-64.
18. National Center for Biotechnology Information dbSNP database, wwwr.ncbi.nlm.nih.gov/SNP/snp-ref.cgi?rs=1799853 (accessed 2008 Mar 30).
19. Rettie AE, Wienkers LC, Gonzalez FJ et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4:39- 42.
20. Steward DJ, Haining RL, Henne KR et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 1997; 7:361-7.
21. Higashi MK, Veenstra DL, Kondo LM et al. Association between CYP2C9 genetic variants and anticoagulation- related outcomes during warfarin therapy. JAMA. 2002; 287:1690-8.
22. Coezy E, Borgna JL, Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 1982;42:317-23.
23. Lim YC, Desta Z, Flockhart DA et al. Endoxifen (4-hydroxy-N-desmethyl- tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005; 55:471-8.
24. Stearns V, Johnson MD, Rae JM et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95:1758-64.
25. Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther. 2008; 83:160-6.
26. Kirchheiner J. CYP2D6 phenotype prediction from genotype: which system is the best? Clin Pharmacol Ther. 2008; 83:225-7.
27. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005; 5:6-13.
28. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002; 3:229-43.
29. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004; 369:23-37.
30. Leon JD, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psycho-somatics. 2006; 47:75-85.
31. Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005; 97:30-9.
32. Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007; 101:113-21.
33. Weinshilboum RM, Sladek SL. Mercap-topurine pharmacogenetics: monogenic inheritance of erythrocyte thiopunne methyltransferase activity. Am J Hum Genet. 1980; 32:651-62.
34. McLeod HL, Siva C. The thiopunne S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics. 2002; 3:89-98.
35. Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Momt. 2004; 26:186-91.
36. Krynetski EY, Schuetz JD, Galpin AJ et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci. 1995;92:949-53.
37. Szumlanski C, Otterness D, Her C et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 1996; 15:17-30.
38. Otterness D, Szumlanski C, Lennard L et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther. 1997; 62:60-73.
39. Wang L, Sullivan W, Toft D et al. Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics. 2003; 13:555-64.
40. Wang L, Nguyen TV, McLaughlin RW et al. Human thiopurine S- methyltransferase pharmacogenetics: variant allozyme misfolding and ag- gresome formation. Proc Natl Acad Sci. 2005; 102:9394-9.
41. Leipold G, Schutz E, Haas JP et al. Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis Rheum. 1997;40:1896-8.
42. Imuran (azathioprine) package insert. San Diego: Prometheus Laboratories; 2008 May.
43. Li T, Chang CY, Jin DY et al. Identification of the gene for vitamin K epoxide reductase. Nature. 2004; 427:541-4.
44. Rost S, Fregin A, Ivaskevicius V et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004; 427:537-41.
45. Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005; 352: 2285-93.
46. Veenstra DL, You JH, Rieder MJ et al. Association of vitamin K epoxide reductase complex 1 (VKORCl) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics. 2005; 15:687-91.
47. Obayashi K, Nakamura K, Kawana J et al. VKORCl gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther. 2006;80:169-78.
48. Aquilante CL, Langaee TY, Lopez LM et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther. 2006;79:291-302.
49. Yuan HY, Chen JJ, Lee MT et al. A novel functional VKORCl promoter polymorphism is associated with inter-individual and mter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14:1745-51.
50. Takahashi H, Wilkinson GR, Nutescu EA et al. Different contributions of polymorphisms in VKORCl and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African- Americans. Pharmacogenet Genomics. 2006; 16:101-10.
51. Rathz DA, Brown KM, Kramer LA et al. Amino acid 49 polymorphisms of the human beta 1-adrenergic receptor affect agonist-promoted trafficking. J Cardw- vasc Pharmacol. 2002; 39:155-60.
52. Mason DA, Moore JD, Green SA et al. A gain-of-function polymorphism in a G- protein coupling domain of the human betal-adrenergic receptor. J Biol Chem. 1999;274:12670-4.
53. Johnson JA, Zineh I, Puckett BJ et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther. 2003; 74:44-52.
54. Liu J, Liu ZQ, Yu BN et al. Betal- adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther. 2006; 80:23-32.
55. Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy. 2007; 27:874-87.
56. Kwon JM, Goate AM. The candidate gene approach. Alcohol Res Health. 2000; 24:164-8.
57. Menke MN, Strauss JF 3rd. Genetic approaches to polycystic ovarian syndrome. Curr Opin Obstet Gynecol 2007; 19:355-9.
58. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet. 2005; 6:95-108.
59. D'Andrea G, D'Ambrosio RL, Di Perna P et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005; 105:645- 9.
60. Kathiresan S, Newton-Cheh C, Gerszten RE. On the interpretation of genetic association studies. Eur Heart J. 2004; 25:1378-81.
61. Tilsor. MD 3rd, Ro CY. The candidate gene approach to susceptibility for abdominal aortic aneurysm: TIMP1, HLA-DR-15, ferritin light chain, and collagen XI-alpha-1. Ann N Y Acad Sci. 2006; 1085:282-90.
62. Zhu M, Zhao S. Candidate gene identification approach: progress and challenges Int J Bwl Sci 2007;3:420-7. 63. Wang WY, Barratt BJ, Clayton DG et al. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet. 2005;6:109-18.
63. Daly MJ, Rioux JD, Schaffner SF et al. High-resolution haplotype structure in the human genome. Nat Genet. 2001; 29:229 32.
64. Pe'er I, de Bakker PI, Mailer J et al. Evaluating and improving power in whole- genome association studies using fixed marker sets. Nat Genet. 2006; 38:663-7. 66. Klein R], Zeiss C, Chew E et al. Complement factor H polymorphism in age- related macular degeneration. Science. 2005; 308:385-9.
65. Sandhu MS, Waterworth DM, Debenham SI. et al. LDL-cholesterol concentrations: a genome-wide association study. Lancet. 2008; 371:483-91.
66. Samani NJ, Erdmann J, Hall AS et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007;357:443-53. 69. Florez JC, Jablonski KA, Bayley N et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl ) Med. 2006; 355:241-50.
67. International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007; 357:851-62.
68. Hunter DJ, Kraft P. Drinking from the fire hose-statistical issues in genomewide association studies. N Engl J Med. 2007; 357:436-9. 72. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007; 447:661-78.
69. Hinohara K, Nakajima T, Takahashi M et al. Replication of the association between a chromosome 9p21 polymorphism and coronary artery disease in Japanese and Korean populations. J Hum Genet. 2008; 53:357-9.
70. Hannon GJ, Beach D. p 15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 1994; 371:257-61. 75. Mohapatra R, Tran M, Gore JM et al. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era. Am Heart J. 2005; 150:19-2(5.
71. Kmdmark A, Jawaid A, Harbron CG et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathol- ogy suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008; 8:186-95.
72. Food and Drug Administration. Table of valid genomic biomarkers in the context of approved drug labels,www.fda.gov/cder/genomics/genomic-biomarkers- table.htm (accessed 2009 Jan 27).
73. Food and Drug Administration. Information for healthcare professionals: carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics).www.fda.gov/cder/drug/InfoSheets/HCP/carbamazepineHCP.htm (accessed 2008 Mar 30).
74. Hung SI, Chung WH, Jee SH et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Phar- macogenet Genomics. 2006; 16:297-306.
75. Man CB, Kwan P, Baum L et al. Association between HLA-BT502 allele and antiepileplic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48:1015-8.
76. Alfirevic A, Jorgensen AL, Williamson PR et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006; 7:813-8.
77. Lonjou C, Thomas L, Borot N et al. A marker for Stevens-Johnson syndrome. Ethnicity matters. Pharmacogenomics J. 2006; 6:265-8.
78. Allele frequencies in worldwide populations,www.allelefrequencies.net/ test/defaultl asp (accessed 2008 Mar 30).
79. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004; 5:835-43.
80. Ciotti M, Basu N, Brangi M et al. Glucuronidation of 7-ethyl-10- hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun. 1999; 260:199-202.
81. Hall D, Ybaeta G, Destro-Bisol G et al. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics. 1999; 9:591-9.
82. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyl transferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sei. 1998;95:8170-4.
83. Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucurono-syltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22:1382-8.
84. Marcuello E, Altes A, Menoyo A et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer. 2004; 91:678-82.
85. Massacesi C, Terrazzino S, Marcucci F et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer. 2006; 106:1007-16. 91. Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle-will we get our wish? N Engl J Med. 2008; 358:105-7.
86. Haga SB, Thummel KE, Burke W. Adding pharmacogenetics information to drug labels: lessons learned. Pharmaco- genet Genomics. 2006; 16:847-54.
87. Lesko LJ, Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov. 2004; 3:763-9.
88. American Association for Clinical Chemistry. Implementing pharmacogenetics into a molecular diagnostics reference lab. www.aacc.org/events/ expert-access/2006/implementpgx/Pages/default.aspx (accessed 2009 Jan 12).
89. Tucker L. Pharmacogenomics: a primer for policymakers, www.nhpf.org/pdfs-bp/BPJ-harmacogenomics-01-28-08. pdf (accessed 2008 Jul 1).
90. Genetic Alliance. Genetic testing. www.geneticalliance.org/ws-display. asp?filter=pohcy.genetic.testing (accessed 2009 Jan 27).
91. Hudson KL, Murphy JA, Kaufman DJ et al. Oversight of US genetic testing laboratories. Nat Biotechnol. 2006; 24:1083- 90.
92. McGovern MM, Elles R, Ronchi E et al. Molecular genetic testing in the United States: comparison with international practice. Genet Test. 2008; 12:187-93
93. Arup Laboratories, www.aruplab.com (accessed 2008 Jul 1).
94. Genelex. www.healthanddna.com (accessed 2008 Jul 1).
95. Genomas Inc. www.genomas.net (accessed 2008 Jul 1).
96. Laboratory Corporation,www.labcorp.com (accessed 2008 Jul 1).
97. Molecular Diagnostics Laboratories. www.mdl-labs.com (accessed 2008 Jul 1).
98. GXL Laboratories, www.pgxlab.com (accessed 2008 Jul 1).
99. Prometheus Therapeutic & Diagnostics. www.prometheuslabs.com (accessed 2008 Jul 1).
100. Quest Diagnostics,www.questdiagnostics.com (accessed 2008 Jul 1).
101. Specialty Laboratories,www.specialtylabs.com (accessed 2008 Jul 1).
102. Bussey HI, Wittkowsky AK, Hylek EM et al. Genetic testing for warfarin dosing? Not yet ready for prime time. Pharmacotherapy. 2008;28:141-3.
103. Hahn KK, Wolff JJ, Kolesar JM. Pharmacogenetics and irinotecan therapy. Am J Health-Syst Pharm. 2006; 63:2211-7.
104. Thompson CA. Genotyping systems for drug-metabolizing enzymes go clinical. Am J Health-Syst Pharm. 2006; 63:12,14, 16. News.
105. National Academy of Clinical Biochemistry. Draft guidelines and recommendations for laboratory analysis and application of pharmacogenetics to clinical practice. www.aacc.org/SiteCollectionDocuments/NACB/LMPG/ Pharmacogentics/complete-PGx-LMPG-Dec-2007.pdf (accessed 2008 Jul 1).
106. Strattera (atomoxetine) package insert. Indianapolis: Eli Lilly and Company; 2002.
107. Sconce EA, Khan Tl, Wynne HA et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005; 106:2329-33.
108. Tham LS, Goh BC, Nafziger A et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Then 2006; 80:346-55.
109. Millican EA, Lenzini PA, Milligan PE et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood. 2007; 110:1511-5.
110. Wu AH, Wang P, Smith A et al. Effect of ethnicity and a comparison of dosing algorithms for warfarin using genotyping for CYP 2C9 and the vitamin K reductase complex 1. Pharmacogenomics. 2008;9:169-78.
111. Carlson RW, Moench SJ, Hammond ME et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Cane Netw. 2006;4(suppl3):Sl-22.
112. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med. 2007; 9:819-25.
113. Flockhart DA, O'Kane D, Williams MS et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008; 10:139-50.
114. Suther S, Goodson P. Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature. Genet Med. 2003; 5:70-6.
115. Guttmacher AE, Porteous ME, Mclnerney JD. Educating health-care professionals about genetics and genomics. Nat Rev Gen. 2007;8:151-7.
116. Haga SB, Burke W. Pharmacogenetic testing: not as simple as it seems. Genet Med. 2008; 10:391-5.